#BEGIN_DRUGCARD DB08894

# AHFS_Codes:
20:16

# ATC_Codes:
B03XA04

# Absorption:
Tmax, SubQ dose = 48 hours;  
Bioavailability, SubQ dose = 46%;
Peginesatide does not accumulate when administered every 4 weeks following intravenous or subcutaneous administration.

# Biotransformation:
Preclinical radiolabeled peginesatide study indicated that peginesatide is not metabolized.

# Brand_Mixtures:
Not Available

# Brand_Names:
Omontys

# CAS_Registry_Number:
913976-27-9

# ChEBI_ID:
66895

# Chemical_Formula:
(C2H4O)n(C2H4O)nC229H344N62O58S6

# Chemical_IUPAC_Name:
Not Available

# Chemical_Structure:
Not Available

# Creation_Date:
2013-06-01 16:45:28 -0600

# DPD_Drug_ID_Number:
Not Available

# Description:
Peginesatide is a synthetic peptide attached to polyethylene glycol for the treatment of anemia. The polyethylene glycol moiety helps make the drug less immunogenic and prolongs its plasma half-life. Chemically, peginesatide is designed to mimic the pharmacological activity of erythropoietin, but is not a replica of the structure itself. Peginesatide consists of two 21-amino acid chains that are covalently bonded by a linker derived from iminodiacetic acid and β-alanine. FDA approved March 27, 2012.

# Dosage_Forms:
Solution	Intravenous

# Drug_Category:
Colony Stimulating Factor
Hematopoietic Agents

# Drug_Interactions:
Not Available

# Drug_Reference:
22188389	Woodburn KW, Holmes CP, Wilson SD, Fong KL, Press RJ, Moriya Y, Tagawa Y: Absorption, distribution, metabolism and excretion of peginesatide, a novel erythropoiesis-stimulating agent, in rats. Xenobiotica. 2012 Jul;42(7):660-70. doi: 10.3109/00498254.2011.649310. Epub 2011 Dec 22.
23318685	Woodburn KW, Fong KL, Wilson SD, Sloneker S, Strzemienski P, Solon E, Moriya Y, Tagawa Y: Peginesatide clearance, distribution, metabolism, and excretion in monkeys following intravenous administration. Drug Metab Dispos. 2013 Apr;41(4):774-84. doi: 10.1124/dmd.112.048033. Epub 2013 Jan 14.
23506424	Schmid H: Peginesatide for the treatment of renal disease-induced anemia. Expert Opin Pharmacother. 2013 May;14(7):937-48. doi: 10.1517/14656566.2013.780695. Epub 2013 Mar 18.

# Drug_Type:
Approved
Small Molecule

# Experimental_Caco2_Permeability:
Not Available

# Experimental_LogP_Hydrophobicity:
Not Available

# Experimental_Logs:
Not Available

# Experimental_Water_Solubility:
Not Available

# Food_Interactions:
Not Available

# GenBank_ID:
Not Available

# Generic_Name:
Peginesatide

# HET_ID:
Not Available

# Half_Life:
IV dose, healthy subjects = 25.0 ± 7.6 hours;
SubQ, healthy subjects = 53.0 ± 17.7 hours;
IV dose, dialysis patients = 47.9 ± 16.5 hours;

# InChI_Identifier:
Not Available

# InChI_Key:
Not Available

# Indication:
Peginesatide is used for the treatment of anemia due to chronic kidney disease (CKD) in adult patients on dialysis

# KEGG_Compound_ID:
Not Available

# KEGG_Drug_ID:
D09947

# LIMS_Drug_ID:
8910

# Mechanism_Of_Action:
Peginesatide binds to and activates the human erythropoietin receptor and stimulates erythropoiesis in human red cell precursors in vitro.

# Melting_Point:
Not Available

# Molecular_Weight_Avg:
Not Available

# Molecular_Weight_Mono:
Not Available

# Organisms_Affected:
Humans and other mammals

# PDB_Experimental_ID:
Not Available

# PDB_Homology_ID:
Not Available

# PDRhealth_Link:
Not Available

# Pathways:
Not Available

# PharmGKB_ID:
Not Available

# Pharmacology:
Peginesatide increases the reticulocyte count and levels of hemoglobin. It also increases RBC count, hematocrit, and soluble transferrin receptor protein in a dose-dependent manner.

# Predicted_LogP_Hydrophobicity:
0

# Predicted_LogS:
0

# Predicted_Water_Solubility:
Not Available

# Primary_Accession_No:
DB08894

# Protein_Binding:
Peginesatide does not bind to serum albumin or lipoprotein as demonstrated in in-vitro studies.

# PubChem_Compound_ID:
Not Available

# PubChem_Substance_ID:
Not Available

# RxList_Link:
http://www.rxlist.com/omontys-drug.htm

# Salts:
Peginesatide acetate

# Secondary_Accession_No:
Not Available

# Smiles_String_canonical:
Not Available

# Smiles_String_isomeric:
Not Available

# State:
liquid

# Structure:
1

# SwissProt_ID:
Not Available

# SwissProt_Name:
Not Available

# Synonyms:
Erythropoiesis-Stimulating Agent (ESA)
Hematide

# Synthesis_Reference:
Not Available

# Toxicity:
The most common adverse events (≥10%) are dyspnea, diarrhea, nausea, cough, and arteriovenous fistula site complication.

# Update_Date:
2013-06-01 23:12:08 -0600

# Wikipedia_Link:
http://en.wikipedia.org/wiki/Peginesatide

# pKa_Isoelectric_Point:
6.0 ± 0.3

# Drug_Target_1_Cellular_Location:
Cell membrane
single-pass type I membrane protein. Isoform EPOR-S:Secreted protein. Isoform EPOR-S

# Drug_Target_1_Chromosome_Location:
Not Available

# Drug_Target_1_Drug_References:
23318685	Woodburn KW, Fong KL, Wilson SD, Sloneker S, Strzemienski P, Solon E, Moriya Y, Tagawa Y: Peginesatide clearance, distribution, metabolism, and excretion in monkeys following intravenous administration. Drug Metab Dispos. 2013 Apr;41(4):774-84. doi: 10.1124/dmd.112.048033. Epub 2013 Jan 14.

# Drug_Target_1_Essentiality:
Non-Essential

# Drug_Target_1_GenAtlas_ID:
EPOR

# Drug_Target_1_GenBank_ID_Gene:
M60459

# Drug_Target_1_GenBank_ID_Protein:
182245

# Drug_Target_1_GeneCard_ID:
EPOR

# Drug_Target_1_Gene_Name:
EPOR

# Drug_Target_1_Gene_Sequence:
>1527 bp
ATGGACCACCTCGGGGCGTCCCTCTGGCCCCAGGTCGGCTCCCTTTGTCTCCTGCTCGCT
GGGGCCGCCTGGGCGCCCCCGCCTAACCTCCCGGACCCCAAGTTCGAGAGCAAAGCGGCC
TTGCTGGCGGCCCGGGGGCCCGAAGAGCTTCTGTGCTTCACCGAGCGGTTGGAGGACTTG
GTGTGTTTCTGGGAGGAAGCGGCGAGCGCTGGGGTGGGCCCGGGCAACTACAGCTTCTCC
TACCAGCTCGAGGATGAGCCATGGAAGCTGTGTCGCCTGCACCAGGCTCCCACGGCTCGT
GGTGCGGTGCGCTTCTGGTGTTCGCTGCCTACAGCCGACACGTCGAGCTTCGTGCCCCTA
GAGTTGCGCGTCACAGCAGCCTCCGGCGCTCCGCGATATCACCGTGTCATCCACATCAAT
GAAGTAGTGCTCCTAGACGCCCCCGTGGGGCTGGTGGCGCGGTTGGCTGACGAGAGCGGC
CACGTAGTGTTGCGCTGGCTCCCGCCGCCTGAGACACCCATGACGTCTCACATCCGCTAC
GAGGTGGACGTCTCGGCCGGCAACGGCGCAGGGAGCGTACAGAGGGTGGAGATCCTGGAG
GGCCGCACCGAGTGTGTGCTGAGCAACCTGCGGGGCCGGACGCGCTACACCTTCGCCGTC
CGCGCGCGTATGGCTGAGCCGAGCTTCGGCGGCTTCTGGAGCGCCTGGTCGGAGCCTGTG
TCGCTGCTGACGCCTAGCGACCTGGACCCCCTCATCCTGACGCTCTCCCTCATCCTCGTG
GTCATCCTGGTGCTGCTGACCGTGCTCGCGCTGCTCTCCCACCGCCGGGCTCTGAAGCAG
AAGATCTGGCCTGGCATCCCGAGCCCAGAGAGCGAGTTTGAAGGCCTCTTCACCACCCAC
AAGGGTAACTTCCAGCTGTGGCTGTACCAGAATGATGGCTGCCTGTGGTGGAGCCCCTGC
ACCCCCTTCACGGAGGACCCACCTGCTTCCCTGGAAGTCCTCTCAGAGCGCTGCTGGGGG
ACGATGCAGGCAGTGGAGCCGGGGACAGATGATGAGGGCCCCCTGCTGGAGCCAGTGGGC
AGTGAGCATGCCCAGGATACCTATCTGGTGCTGGACAAATGGTTGCTGCCCCGGAACCCG
CCCAGTGAGGACCTCCCAGGGCCTGGTGGCAGTGTGGACATAGTGGCCATGGATGAAGGC
TCAGAAGCATCCTCCTGCTCATCTGCTTTGGCCTCGAAGCCCAGCCCAGAGGGAGCCTCT
GCTGCCAGCTTTGAGTACACTATCCTGGACCCCAGCTCCCAGCTCTTGCGTCCATGGACA
CTGTGCCCTGAGCTGCCCCCTACCCCACCCCACCTAAAGTACCTGTACCTTGTGGTATCT
GACTCTGGCATCTCAACTGACTACAGCTCAGGGGACTCCCAGGGAGCCCAAGGGGGCTTA
TCCGATGGCCCCTACTCCAACCCTTATGAGAACAGCCTTATCCCAGCCGCTGAGCCTCTG
CCCCCCAGCTATGTGGCTTGCTCTTAG

# Drug_Target_1_General_Function:
Involved in transmembrane receptor activity

# Drug_Target_1_General_References:
10374881	Wakioka T, Sasaki A, Mitsui K, Yokouchi M, Inoue A, Komiya S, Yoshimura A: APS, an adaptor protein containing Pleckstrin homology (PH) and Src homology-2 (SH2) domains inhibits the JAK-STAT pathway in collaboration with c-Cbl. Leukemia. 1999 May;13(5):760-7.
10388848	Zhan H, Liu B, Reid SW, Aoki KH, Li C, Syed RS, Karkaria C, Koe G, Sitney K, Hayenga K, Mistry F, Savel L, Dreyer M, Katz BA, Schreurs J, Matthews DJ, Cheetham JC, Egrie J, Giebel LB, Stroud RM: Engineering a soluble extracellular erythropoietin receptor (EPObp) in Pichia pastoris to eliminate microheterogeneity, and its complex with erythropoietin. Protein Eng. 1999 Jun;12(6):505-13.
11722595	Motohashi T, Nakamura Y, Osawa M, Hiroyama T, Iwama A, Shibuya A, Nakauchi H: Increased cell surface expression of C-terminal truncated erythropoietin receptors in polycythemia. Eur J Haematol. 2001 Aug;67(2):88-93.
11756159	Kirito K, Nakajima K, Watanabe T, Uchida M, Tanaka M, Ozawa K, Komatsu N: Identification of the human erythropoietin receptor region required for Stat1 and Stat3 activation. Blood. 2002 Jan 1;99(1):102-10.
11784712	Meunier C, Bordereaux D, Porteu F, Gisselbrecht S, Chretien S, Courtois G: Cloning and characterization of a family of proteins associated with Mpl. J Biol Chem. 2002 Mar 15;277(11):9139-47. Epub 2002 Jan 9.
12027890	Hortner M, Nielsch U, Mayr LM, Heinrich PC, Haan S: A new high affinity binding site for suppressor of cytokine signaling-3 on the erythropoietin receptor. Eur J Biochem. 2002 May;269(10):2516-26.
12746455	Friedman AD, Nimbalkar D, Quelle FW: Erythropoietin receptors associate with a ubiquitin ligase, p33RUL, and require its activity for erythropoietin-induced proliferation. J Biol Chem. 2003 Jul 18;278(29):26851-61. Epub 2003 May 13.
1324524	Nakamura Y, Komatsu N, Nakauchi H: A truncated erythropoietin receptor that fails to prevent programmed cell death of erythroid cells. Science. 1992 Aug 21;257(5073):1138-41.
1654273	Ehrenman K, St John T: The erythropoietin receptor gene: cloning and identification of multiple transcripts in an erythroid cell line OCIM1. Exp Hematol. 1991 Oct;19(9):973-7.
1657727	Todokoro K, Kuramochi S, Nagasawa T, Abe T, Ikawa Y: Isolation of a cDNA encoding a potential soluble receptor for human erythropoietin. Gene. 1991 Oct 15;106(2):283-4.
1664413	Penny LA, Forget BG: Genomic organization of the human erythropoietin receptor gene. Genomics. 1991 Dec;11(4):974-80.
1668606	Noguchi CT, Bae KS, Chin K, Wada Y, Schechter AN, Hankins WD: Cloning of the human erythropoietin receptor gene. Blood. 1991 Nov 15;78(10):2548-56.
1668607	Maouche L, Tournamille C, Hattab C, Boffa G, Cartron JP, Chretien S: Cloning of the gene encoding the human erythropoietin receptor. Blood. 1991 Nov 15;78(10):2557-63.
2163695	Winkelmann JC, Penny LA, Deaven LL, Forget BG, Jenkins RB: The gene for the human erythropoietin receptor: analysis of the coding sequence and assignment to chromosome 19p. Blood. 1990 Jul 1;76(1):24-30.
2163696	Jones SS, D'Andrea AD, Haines LL, Wong GG: Human erythropoietin receptor: cloning, expression, and biologic characterization. Blood. 1990 Jul 1;76(1):31-5.
7534299	Tauchi T, Feng GS, Shen R, Hoatlin M, Bagby GC Jr, Kabat D, Lu L, Broxmeyer HE: Involvement of SH2-containing phosphotyrosine phosphatase Syp in erythropoietin receptor signal transduction pathways. J Biol Chem. 1995 Mar 10;270(10):5631-5.
8506290	de la Chapelle A, Traskelin AL, Juvonen E: Truncated erythropoietin receptor causes dominantly inherited benign human erythrocytosis. Proc Natl Acad Sci U S A. 1993 May 15;90(10):4495-9.
8662530	Livnah O, Stura EA, Johnson DL, Middleton SA, Mulcahy LS, Wrighton NC, Dower WJ, Jolliffe LK, Wilson IA: Functional mimicry of a protein hormone by a peptide agonist: the EPO receptor complex at 2.8 A. Science. 1996 Jul 26;273(5274):464-71.
8662939	Middleton SA, Johnson DL, Jin R, McMahon FJ, Collins A, Tullai J, Gruninger RH, Jolliffe LK, Mulcahy LS: Identification of a critical ligand binding determinant of the human erythropoietin receptor. Evidence for common ligand binding motifs in the cytokine receptor family. J Biol Chem. 1996 Jun 14;271(24):14045-54.
9774108	Syed RS, Reid SW, Li C, Cheetham JC, Aoki KH, Liu B, Zhan H, Osslund TD, Chirino AJ, Zhang J, Finer-Moore J, Elliott S, Sitney K, Katz BA, Matthews DJ, Wendoloski JJ, Egrie J, Stroud RM: Efficiency of signalling through cytokine receptors depends critically on receptor orientation. Nature. 1998 Oct 1;395(6701):511-6.
9808045	Livnah O, Johnson DL, Stura EA, Farrell FX, Barbone FP, You Y, Liu KD, Goldsmith MA, He W, Krause CD, Pestka S, Jolliffe LK, Wilson IA: An antagonist peptide-EPO receptor complex suggests that receptor dimerization is not sufficient for activation. Nat Struct Biol. 1998 Nov;5(11):993-1004.
9974392	Livnah O, Stura EA, Middleton SA, Johnson DL, Jolliffe LK, Wilson IA: Crystallographic evidence for preformed dimers of erythropoietin receptor before ligand activation. Science. 1999 Feb 12;283(5404):987-90.

# Drug_Target_1_HGNC_ID:
HGNC:3416

# Drug_Target_1_HPRD_ID:
00587

# Drug_Target_1_ID:
720

# Drug_Target_1_Locus:
19p13.3-p13.2

# Drug_Target_1_Molecular_Weight:
55066

# Drug_Target_1_Name:
Erythropoietin receptor

# Drug_Target_1_Number_of_Residues:
508

# Drug_Target_1_PDB_ID:
1CN4

# Drug_Target_1_Pathway:
Not Available

# Drug_Target_1_Pfam_Domain_Function:
PF00041	fn3

# Drug_Target_1_Protein_Sequence:
>Erythropoietin receptor precursor
MDHLGASLWPQVGSLCLLLAGAAWAPPPNLPDPKFESKAALLAARGPEELLCFTERLEDL
VCFWEEAASAGVGPGNYSFSYQLEDEPWKLCRLHQAPTARGAVRFWCSLPTADTSSFVPL
ELRVTAASGAPRYHRVIHINEVVLLDAPVGLVARLADESGHVVLRWLPPPETPMTSHIRY
EVDVSAGNGAGSVQRVEILEGRTECVLSNLRGRTRYTFAVRARMAEPSFGGFWSAWSEPV
SLLTPSDLDPLILTLSLILVVILVLLTVLALLSHRRALKQKIWPGIPSPESEFEGLFTTH
KGNFQLWLYQNDGCLWWSPCTPFTEDPPASLEVLSERCWGTMQAVEPGTDDEGPLLEPVG
SEHAQDTYLVLDKWLLPRNPPSEDLPGPGGSVDIVAMDEGSEASSCSSALASKPSPEGAS
AASFEYTILDPSSQLLRPWTLCPELPPTPPHLKYLYLVVSDSGISTDYSSGDSQGAQGGL
SDGPYSNPYENSLIPAAEPLPPSYVACS

# Drug_Target_1_Reaction:
Not Available

# Drug_Target_1_Signals:
1-24

# Drug_Target_1_Specific_Function:
Isoform EPOR-T, missing the cytoplasmic tail, acts as a dominant-negative receptor of EPOR-mediated signaling

# Drug_Target_1_SwissProt_ID:
P19235

# Drug_Target_1_SwissProt_Name:
EPOR_HUMAN

# Drug_Target_1_Synonyms:
EPO-R
Erythropoietin receptor precursor

# Drug_Target_1_Theoretical_pI:
4.37

# Drug_Target_1_Transmembrane_Regions:
251-273

#END_DRUGCARD DB08894
